Curexo Inc (060280) - Total Liabilities
Based on the latest financial reports, Curexo Inc (060280) has total liabilities worth ₩9.36 Billion KRW (≈ $6.34 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Curexo Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Curexo Inc - Total Liabilities Trend (2006–2024)
This chart illustrates how Curexo Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Curexo Inc balance sheet assets.
Curexo Inc Competitors by Total Liabilities
The table below lists competitors of Curexo Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Finwise Bancorp
NASDAQ:FINW
|
USA | $783.94 Million |
|
Organogenesis Holdings Inc
NASDAQ:ORGO
|
USA | $123.85 Million |
|
United Pharm
KO:033270
|
Korea | ₩103.96 Billion |
|
Barings Participation Investors (the Trust)
NYSE:MPV
|
USA | $44.52 Million |
|
Melar Acquisition Corp. I Class A Ordinary Shares
NASDAQ:MACI
|
USA | $10.89 Million |
|
Magni Tech Industries Bhd
KLSE:7087
|
Malaysia | RM148.05 Million |
|
Crown Reserve Acquisition Corp. I Class A Ordinary Shares
NASDAQ:CRAC
|
USA | $2.22 Million |
|
BAPCOR LTD.
F:0BS
|
Germany | €971.27 Million |
Liability Composition Analysis (2006–2024)
This chart breaks down Curexo Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 060280 equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Curexo Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Curexo Inc (2006–2024)
The table below shows the annual total liabilities of Curexo Inc from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩9.20 Billion ≈ $6.24 Million |
+32.58% |
| 2023-12-31 | ₩6.94 Billion ≈ $4.70 Million |
-58.48% |
| 2022-12-31 | ₩16.72 Billion ≈ $11.33 Million |
-9.17% |
| 2021-12-31 | ₩18.40 Billion ≈ $12.47 Million |
+350.64% |
| 2020-12-31 | ₩4.08 Billion ≈ $2.77 Million |
+29.84% |
| 2019-12-31 | ₩3.15 Billion ≈ $2.13 Million |
-4.96% |
| 2018-12-31 | ₩3.31 Billion ≈ $2.24 Million |
-31.91% |
| 2017-12-31 | ₩4.86 Billion ≈ $3.29 Million |
-5.93% |
| 2016-12-31 | ₩5.17 Billion ≈ $3.50 Million |
-79.43% |
| 2015-12-31 | ₩25.12 Billion ≈ $17.02 Million |
-4.84% |
| 2014-12-31 | ₩26.39 Billion ≈ $17.89 Million |
+492.85% |
| 2013-12-31 | ₩4.45 Billion ≈ $3.02 Million |
+128.33% |
| 2012-12-31 | ₩1.95 Billion ≈ $1.32 Million |
-96.50% |
| 2011-12-31 | ₩55.67 Billion ≈ $37.73 Million |
+1417.14% |
| 2010-12-31 | ₩3.67 Billion ≈ $2.49 Million |
-66.86% |
| 2009-12-31 | ₩11.07 Billion ≈ $7.50 Million |
-5.03% |
| 2008-12-31 | ₩11.66 Billion ≈ $7.90 Million |
-3.95% |
| 2007-12-31 | ₩12.14 Billion ≈ $8.23 Million |
+29.52% |
| 2006-12-31 | ₩9.37 Billion ≈ $6.35 Million |
-- |
About Curexo Inc
Curexo Inc. engages in the development and sale of medical devices in Korea and internationally. Its products include ROBIN, a robot system that guides needle path induring CT-guided interventional procedure; Baidy, a medical device that assists labor by increasing intrauterine pressure which helps natural childbirth; artificial joint surgical robot; and Gait rehabilitation robot. The company als… Read more